Introduction
The aim of antiepileptic drug (AED) therapy is to achieve seizure control using a single agent. However, this can be only successful in approximately two thirds of patients whether old or new AEDs are used. 1, 2 Levetiracetam (LEV) is a novel antiepileptic drug (AED) which has been approved as adjunctive treatment for adults with partial onset seizures. Its effectiveness was established in three multicenter, well-controlled pivotal trials. [3] [4] [5] In addition, LEV is well tolerated with a favorable pharmacokinetic profile that includes minimal protein binding, lack of hepatic metabolism, and twice a day dosing. 6 These features and others make it ideal for use as monotherapy.
We have previously demonstrated the efficacy of levetiracetam as monotherapy in newly diagnosed naïve epilepsy patients and in patients with chronic difficult to control epilepsy who were followed for 6 months. 7 However, the efficacy and long-term continuation rate of LEV monotherapy at 1 year of treatment is currently unknown. In this study, we sought to evaluate our 1-year experience with LEV monotherapy, examining the seizure control and Patients began LEV either as first line therapy (n = 11) or were converted to LEV monotherapy (n = 35) after failing prior antiepileptic medications (AEDs). Patients were followed up to 12 months after LEV started. The majority of these patients were able to continue on LEV and a small number of patients discontinued LEV secondary to lack of efficacy. One third of the non-seizure free group at 6 months of follow-up had worse seizure control at 12 months and two thirds had the same or better seizure control. Our 1-year follow-up data of LEV as monotherapy suggests that LEV can be effective and well tolerated in adults with either new or difficult to control epilepsy. A prospective, large, long-term double-blind study is needed to confirm this finding. # 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved. treatment retention rates in our clinic population and comparing them with our 6 months clinical experience.
Methods
In this report, we analyzed the data of 31 patients previously reported, 7 and an additional 16 patients were identified after retrospectively reviewing the medical records of our patients who were diagnosed with epilepsy after having two unprovoked seizures during the years 2000-2003. Six of the original 37 patients previously reported were not included because further evaluation of their diagnosis with Video-EEG Monitoring revealed diagnosis other than epilepsy. We identified patients who received LEV as monotherapy either as a first line or add-on agent with subsequent conversion to LEV monotherapy. We reviewed patients' demographic data, diagnostic evaluation for epilepsy, seizure types, and seizure frequency prior to and following initiation of LEV monotherapy. All patients had follow-up visits at regular intervals every 2 months, or at shorter intervals if medically necessary. All patients had their LEV dose titrated up to maximal tolerated dose or up to 5000 mg/day, and for elderly patients the dose was titrated up to 2000 mg/day or up to seizure freedom. In this observational study, we compared seizure counts for the previous 2 months as baseline, prior to initiation of LEV treatment, to seizure counts at six months and at 12 months of follow-up after LEV was started and maintained as therapy. Seizure frequency was determined using a seizure diary completed by each patient or their caregivers, which is a standard practice in our clinic. The analysis of seizure-freedom and seizure reductions rates was based on the number of patients who completed the 1-year follow-up. Adverse events (AEs) while on LEV were also noted at each clinic visit. Blood work including CBC, LFTs were obtained at baseline, 6 months, and at 1 year of treatment.
Results
We identified 46 patients (32 females, 14 males), ages 18-91, (mean 30.8) with a history of partial seizures with and without secondarily generalization. The duration of epilepsy prior to LEV treatment ranged from 1-52 years, (mean 14.1 years). Eleven of these patients began LEV as an initial drug therapy. These patients were not taking any AEDs for any period of time prior to starting LEV. Three of the 11 patients had liver disease, and the remaining eight patients chose to start LEV because of its favorable pharmacokinetic and side effect profile. Thirty-five patients converted to LEV monotherapy after they failed several trials of AEDs, which included phenytoin (Dilantin
, and topiramate (Topamax 1 ), (mean 2.2 AEDs). Characteristics and demographics of our two groups of patients are summarized in Tables 1 and 2. At 6 months visit, three patients were lost to follow-up and five patients discontinued treatment secondary to lack of efficacy. Three additional patients discontinued therapy early after starting treatments on LEV at a dose less than 500 mg/day because of side effects, two of whom were started on LEV as a first line agent. Hence, 35 patients remained for analysis in this current study. Of these patients, 26 were converted to LEV after they failed their prior AEDs. Table 3 illustrates changes in seizure frequency at 6 months and at 1 year for the whole group (new onset and chronic epilepsy) as a percentage. At 1 year follow up: nineteen of the 35 (54%) were seizure free for the past 6 months. Eight patients who began LEV as monotherapy were seizure free, whereas the remaining 11 patients who began LEV as add-on therapy became seizure free. Of the remaining patients, 9/35 (25.7%) had more than 50%, but less than 75%, seizure reduction and 4/35 (11.4%) patients had >75% reduction of seizures. One patient had no significant change in seizure frequency. The remaining two patients had more than 25%, but less than 50%, reduction in seizure frequency.
For the 18 seizure-free patients at 6 months, 17 patients (94%) remained seizure free at 12 months; whereas, for the 22 non-seizure free patients at 6 months: 7/22 (31%) patients had worse seizures at 12 months (less than 25% reduction) at 12 months that was not considered clinically relevant and eight patients (36%) had the same seizure control. Two patients (9%) had better seizure control at 1-year follow-up compared to 6 months. These last 2 patients became seizure free after achieving more than 75% reduction of seizures at 6 months visit. Five of the 22 patients discontinued treatment after 6 months secondary to lack of efficacy.
Six patients reported being nervous or irritable within two weeks of starting LEV, either as a single agent (n = 4) or as add-on treatment (n = 2). Of these patients, three discontinued LEV, while the other three patients continued on LEV when their complaints decreased after the first month of therapy. Four patients reported dizziness within days after starting LEV but were able to continue on LEV. No other major AEs were reported. No clinically significant blood abnormalities were detected throughout the study.
Discussion
This study suggests that LEV as monotherapy can be effective and well tolerated in newly diagnosed epilepsy patients as well as for chronic epilepsy patients who failed multiple AEDs prior to LEV treatment. In addition, this study shows a high retention rate of LEV with most patients able to continue on LEV for 12 months. This was true for naïve epilepsy patients who were never tried on AEDs, as well as for patients with difficult to control epilepsy. Of the group as a whole 45% were seizure free at 6 months and 54% were seizure free at 12 months of follow-up. One third of the nonseizure free group at 6 months of follow-up had a clinically non-relevant worse seizure control at 12 months and two thirds had the same or better seizure control.
A previous study of 1422 patients exposed to LEV during its developmental program showed an estimated rate of retention to be 60% after 1 year with 13% of patients becoming seizure free for at least 6 months. 8 In the present study, 82% of our patients remained on LEV for at least 1 year with more than 50% of patients remaining seizure free. Most of these patients (60.7%) had failed more than one AED, while 32% of patients were on dual therapy at the time of conversion. Other open label add-on studies confirm this finding. 9, 10 Retention rate studies are a measurement of efficacy and tolerability of an AED. Comparing retention rates between studies with populations of different settings may not be ideal. Studies utilizing patients from clinical trials may show higher retention rates than chronic refractory epilepsy studies. Patients in clinical trials are less likely to withdraw than patients in clinical practice, with many withdrawals, in these clinical trials are due to problems intrinsic to AED trials. Our higher than previously reported continuation success rates on LEV may be related to the small sampling of patients studied, differences in the severity of underlying disease, selection bias, as well as the lack of double blind randomization. In addition, it is possible that the number of AEDs taken concurrently in the other add-on trials have an effect on the retention rates, as patients on LEV monotherapy are more likely to continue on LEV. Similarly, our lower than previously reported AEs, including the low psychiatric and behavioral complaints in this current study could be related to a lack of pharmacokinetic and pharmacodynamic interactions in our study. It is well known that negative psychotropic effects are increased in patients taking multiple AEDs as compared to those taking a single agent. 11 Patients on monotherapy have far fewer adverse effects than patients on polytherapy. This is the distinction between community practice experience and clinical trials reports. Finally, the improvement in seizure control could be the result of spontaneous remission as there are fluctuations in seizure frequency in epileptic patients. 12 However, the longer seizures persist, the harder they are to control. With an average duration of epilepsy at 13.8 years for the chronic epilepsy patients, it is unlikely that a complete spontaneous remission in seizure frequency could explain all the improvement seen in this population.
